Effects Of Hemodiafiltration Versus Conventional Hemodialysis In Children With Eskd: The Hdf, Heart And Height Study
![](/themes/Mirage2//images/mime2.png)
Göster/ Aç
Tarih
2019Yazar
Shroff, Rukshana
Smith, Colette
Ranchin, Bruno
Bayazit, Aysun K.
Stefanidis, Constantinos J.
Askiti, Varvara
Azukaitis, Karolis
Canpolat, Nur
Ağbaş, Ayşe
Aitkenhead, Helen
Anarat, Ali
Aoun, Bilal
Aofolaju, Daley
Bakkaloglu, Sevcan Azime
Bhowruth, Devina
Borzych-Dużałka, Dagmara
Bulut, Ipek Kaplan
Büscher, Rainer
Deanfield, John
Dempster, Claire
Duzova, Ali
Habbig, Sandra
Hayes, Wesley
Hegde, Shivram
Krid, Saoussen
Licht, Christoph
Litwin, Mieczyslaw
Mayes, Mark
Mir, Sevgi
Nemec, Rose
Obrycki, Lukasz
Paglialonga, Fabio
Picca, Stefano
Samaille, Charlotte
Shenoy, Mohan
Sinha, Manish D.
Spasojevic, Brankica
Stronach, Lynsey
Vidal, Enrico
Vondrák, Karel
Yilmaz, Alev
Zaloszyc, Ariane
Fischbach, Michel
Schmitt, Claus Peter
Schaefer, Franz
Üst veri
Tüm öğe kaydını gösterÖzet
Although studies suggest that hemodiafiltration (HDF) may reduce cardiovascular mortality in adults, data in children are sparse. In this observational multicenter study, the authors compared HDF and hemodialysis (HD) in children with ESKD, finding that annualized changes in well validated subclinical markers of cardiovascular disease, including carotid intima-media thickness SD scores, were lower in HDF and associated with lower 24-hour ambulatory BP and intradialytic weight gain. Height increased only in the HDF cohort. Compared with the HD cohort, the HDF cohort also had better self-reported outcomes, with fewer headaches, less dizziness or cramps, and shorter recovery time after dialysis sessions. The study provides proof-of-concept data that HDF is a safe treatment that may have benefits over conventional HD in children. A randomized trial is required to confirm these findings.,
Bağlantı
http://dx.doi.org/10.1681/ASN.2018100990https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442347/
http://hdl.handle.net/11655/23802